A Metropolitan Transportation Authority rendering shows a conceptual interior of a future Second Avenue Subway station in Harlem, illustrating platform circulation, train clearances and passenger flow ...
Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A novel GLP-1 and amylin receptor agonist reduced HbA1c ...
Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
Cidara Therapeutics soared 250% after strong Phase 2b NAVIGATE trial results for CD388, a novel antiviral for flu prophylaxis. CD388 demonstrated up to 76% efficacy, outperforming many traditional flu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results